This study is comparing two ways to deliver long-acting bronchodilator medicines for Chronic Obstructive Pulmonary Disease (COPD). It will look at whether a nebulizer (which creates a mist you breathe in) delivering Revefenacin and Formoterol works better than a dry powder inhaler (DPI) delivering umeclidinium and vilanterol. The study aims to see if one method improves your breathing capacity (inspiratory capacity) and reduces symptoms more effectively. You might be able to join if you are over 40, have COPD symptoms, and a history of smoking. The study will measure changes in your inspiratory capacity between baseline and week 12 to see which treatment is more effective. The current status of this study is unclear.

Study design

This is a randomized, double-blind study with about 72 participants. It compares two active treatments and two placebo treatments over 13 weeks.

What's involved

You will have a screening visit, a baseline visit, and then take study medication daily for 12 weeks. You will also complete daily diaries and questionnaires.

Compensation

Not stated in the trial record.

Follow-up

Your inspiratory capacity will be measured from baseline (Week 2) through study completion (Week 12).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.